In the first-in-human phase 1 trial of lepodisiran, a novel short-interfering RNA (siRNA) therapy, levels of lipoprotein(a) (Lp(a)) were reduced below the lowest limit of quantitation for nearly nine months. Steven Nissen, MD, summarizes these findings that were presented in a late-breaking science session at the American Heart Association Scientific Sessions 2023 and simultaneously published online in JAMA.